Boston, Massachusetts & Rolle, Switzerland, August 4, 2026
SOPHiA GENETICS has entered into a global multi-year collaboration with AstraZeneca to develop, validate and deploy two companion diagnostics (CDx) designed to support precision oncology therapies. The partnership combines SOPHiA GENETICS’ AI-native diagnostic platform with AstraZeneca’s oncology pipeline to accelerate the identification of patients most likely to benefit from targeted cancer treatments. Under the agreement, SOPHiA GENETICS will advance its Solid Tumor application into a decentralized companion diagnostic while also developing and validating its Hematological Oncology application to support blood cancer therapies. The collaboration reflects the growing importance of AI-powered companion diagnostics, decentralized testing and biomarker-driven precision medicine in improving global access to innovative oncology treatments. By enabling laboratories worldwide to perform standardized genomic testing, the companies aim to reduce barriers to patient identification and expand access to personalized cancer care across multiple healthcare systems.
Global Collaboration Expands Companion Diagnostic Development
The strategic alliance will focus on developing two companion diagnostic programs that support the clinical development and commercialization of AstraZeneca’s precision oncology therapies. Companion diagnostics play an increasingly important role in modern oncology by identifying patients whose tumors carry specific genomic biomarkers that predict treatment response. As part of the collaboration, SOPHiA GENETICS will enhance its Solid Tumor application into a decentralized companion diagnostic while validating its Hematological Oncology application for blood cancer testing. The company’s end-to-end diagnostic capabilities span the entire development continuum, including clinical trial assay development, companion diagnostic validation, regulatory submissions, and global laboratory deployment. This comprehensive approach is designed to accelerate patient enrollment during clinical trials while ensuring validated biomarker testing is available immediately following regulatory approval of new cancer therapies. The collaboration demonstrates the increasing integration of artificial intelligence, genomic medicine, and biomarker-driven drug development within the global pharmaceutical industry.
AI Platform Enables Decentralized Precision Oncology Testing
A central component of the collaboration is the deployment of SOPHiA DDM™, the company’s technology-agnostic, cloud-based AI platform that enables healthcare institutions to perform standardized genomic analyses while benefiting from a global network of shared clinical intelligence. Currently connecting more than 1,000 healthcare institutions across over 75 countries, the platform allows laboratories to conduct validated genomic testing locally without sacrificing consistency or analytical quality. Through the SOPHiA DDM™ MaxCare Program, laboratories can rapidly adopt new genomic applications and integrate companion diagnostics into routine clinical practice. By combining AI-powered genomic analysis, decentralized laboratory testing and real-time clinical insights, the platform supports faster biomarker detection, improved clinical decision-making and broader access to precision oncology therapies. The companies believe this decentralized approach will help ensure that eligible patients can be identified more quickly regardless of geographic location, strengthening global implementation of personalized cancer medicine.
Advertisement
Partnership Advances Data-Driven Precision Medicine
The collaboration highlights the growing demand for data-driven medicine and AI-enabled diagnostics that improve the connection between innovative therapeutics and appropriate patient populations. As targeted therapies continue transforming cancer treatment, companion diagnostics have become essential for selecting patients based on molecular biomarkers and optimizing clinical outcomes. Through this partnership, SOPHiA GENETICS aims to shorten the time between therapy development and clinical adoption by integrating advanced biomarker detection with scalable diagnostic deployment across international healthcare systems. The collaboration also reinforces the company’s broader mission of expanding access to precision oncology, supporting pharmaceutical innovation and improving patient outcomes through AI-powered genomic technologies. By combining advanced diagnostics with AstraZeneca’s oncology expertise, the partnership represents another important step toward delivering personalized treatment strategies that enable clinicians to match the right therapy with the right patient at the right time.
Source: SOPHiA GENETICS, AstraZeneca press release
